Neoadjuvant Anti-Programmed Death-1 Immunotherapy by Pembrolizumab in Resectable Non-Small Cell Lung Cancer: Results of the NEOMUN Trial

Two cycles of pembrolizumab were administered before surgery. The primary objectives were to assess the feasibility and safety of neoadjuvant treatment and evaluate antitumor activity. They analyzed the clinical parameters and pathological, radiological, and metabolic tumor response data.